Is March the month?- March 8 is the vote.
- New name for the company.
- 5X PGX commissioning by the end of March. Gilles has previously indicated that the 5X scale-up provides partners with materials to work with. CZO has also designed an animal trial protocol for the immune booster and may need this material. Closing of the merger would provide CZO with capital and internal capability for a strong PGX partnership. 10X commissioning could be just 5-6 months later.
- Pediatric data for AEZS's test and a licensing deal could happen at any time.
- AEZS pipeline assets may be nearing a clinical trial decision and candidate selection.
It could be a nice launch on NASDAQ. Add some analyst support.